BG Medicine

NEW YORK (GenomeWeb News) – Roche said this week that it will invest CHF 240 million ($258.4 million) in a new diagnostics center at its Penzberg, Germany biotech center near Munich.

BG Medicine this week reported a 257 percent year-over-year increase in third-quarter revenues driven by sales of its BGM Galectin-3 test.

NEW YORK (GenomeWeb News) – BG Medicine said today that revenues in the third quarter rose 258 percent year over year on the sale of it BGM Galectin-3 test.

NEW YORK (GenomeWeb News) – Illumina disclosed in its quarterly filing with the US Securities and exchange Commission that it paid a total consideration of $95.5 million for its acquisition of BlueGnome in July.

BG Medicine said this week that the Centers for Medicare and Medicaid Services have assigned a payment rate for the company's BGM Galectin-3 test under a new analyte-specific Current Procedural Terminology code that will go into effect Jan. 1, 2013.

BG Medicine has appointed Charles Abdalian to executive vice president and chief financial officer. He joins the company from Knome, where he served as chief financial officer.

NEW YORK (GenomeWeb News) – BG Medicine today announced a deal with Kindstar Diagnostics to offer galectin-3 testing services in China.

BG Medicine has appointed Charles Abdalian to be executive VP and chief financial officer. Mike Rogers will be departing the company after three-and-a-half years as CFO.

Agilent has named Lars Holmkvist as a senior vice president and president of its Diagnostics and Genomics group.

This story has been updated to correct a quote citing a BG official saying BNP is a marker of inflammation. In fact, he said that it was a marker of "loading and stretch."

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.